Usana Health Sciences, Inc., a Utah-based nutritional, skincare and dietary products manufacturer, indicates in its recently filed 8-K that it has substantially completed an internal investigation into whether the expense reimbursement policy and other practices at its Chinese affiliate, BabyCare Ltd., were compliant with the Foreign Corrupt Practices Act. The company reports that it is cooperating with the DOJ and the SEC in their investigations of the matter.
February 5, 2019
DOJ and SEC investigating nutritional supplement maker for possible FCPA violations
Related by Topic
New Post
Indonesia-based PT Telkom discloses two U.S. investigations, including an FCPA inquiry
May 1, 2025
News Alert
New Post
Merit Medical Systems discloses SEC inquiry into its China-based subsidiary
May 1, 2025
News Alert
New Post
Federal prosecutors move to terminate Stericycle DPA in FCPA matter
April 28, 2025
News Alert